{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:49:37Z","timestamp":1790668177366,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T00:00:00Z","timestamp":1466985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"European Union FP7","award":["103972"],"award-info":[{"award-number":["103972"]}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["324634"],"award-info":[{"award-number":["324634"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.06.059","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T23:15:35Z","timestamp":1477696535000},"page":"6436-6448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Vector-based genetically modified vaccines: Exploiting Jenner\u2019s legacy"],"prefix":"10.1016","volume":"34","author":[{"given":"Bahar","family":"Ramezanpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ab","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2016.06.059_b0005","article-title":"A brief history of vaccines: smallpox to the present","volume":"33","author":"Hsu","year":"2013","journal-title":"South Dakota Med"},{"key":"10.1016\/j.vaccine.2016.06.059_b0010","unstructured":"TNIAID. Types of Vaccines; 2015. Available from: <http:\/\/www.vaccines.gov\/more_info\/types\/>."},{"issue":"11","key":"10.1016\/j.vaccine.2016.06.059_b0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/MB:29:3:255","article-title":"Overview of vaccines and vaccination","volume":"29","author":"Ada","year":"2005","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2016.06.059_b0025","unstructured":"FDA. FluMist approval; 2003 [cited 2015]. Available from: <http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm094047.htm>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0030","unstructured":"FDA. Recombivax approval FDA; 1983 [cited 2015]. Available from: <http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm110098.htm>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0035","unstructured":"TGA. IMOJEV approval; 2010. Available from: <http:\/\/www.tga.gov.au\/artg\/artg-id-162215>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0040","unstructured":"FDA. Flublok approval; 2013."},{"issue":"4","key":"10.1016\/j.vaccine.2016.06.059_b0045","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2016.06.059_b0050","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3390\/vaccines2040686","article-title":"Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant","volume":"2","author":"Singh","year":"2014","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"35","key":"10.1016\/j.vaccine.2016.06.059_b0060","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1016\/j.vaccine.2015.04.086","article-title":"Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: a quantitative key opinion leader analysis","volume":"33","author":"Ramezanpour","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.059_b0065","unstructured":"Kreijtz JHCM, Ramezanpour B, Fernald KDS, van de Burgwal LHM. GM vaccines: from bench to bedside. CGM; 2014."},{"key":"10.1016\/j.vaccine.2016.06.059_b0070","unstructured":"Espacenet [cited 2015]. Available from: <http:\/\/worldwide.espacenet.com\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0075","unstructured":"RVO. Netherlands Enterprise Agency [cited 2015]. Available from: <http:\/\/english.rvo.nl\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0080","unstructured":"World Health Organisation International Clinical Trials Registry Platform [cited 2015]. Available from: <https:\/\/clinicaltrials.gov\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0085","unstructured":"FDA. US Food and Drug Administration [cited 2014]. Available from: <http:\/\/www.fda.gov>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0090","unstructured":"EMA. European Medicines Agency [cited 2014]. Available from: <http:\/\/www.ema.europa.eu\/ema\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0095","unstructured":"Fiocruz. Oswaldo Cruz Foundation. Available from: <http:\/\/portal.fiocruz.br\/en\/content\/home-ingles>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0100","unstructured":"CDSCO. Central Drugs standard control organisation [cited 2014]. Available from: <http:\/\/cdsco.nic.in\/forms\/Default.aspx>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0105","unstructured":"Medguide India [cited 2014]. Available from: <http:\/\/www.medguideindia.com\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0110","unstructured":"CFDA. China Food and Drug Administration [cited 2014]. Available from: <http:\/\/eng.sfda.gov.cn\/WS03\/CL0755\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0115","unstructured":"SAVIC. South African Vaccination and Immunisation Centre [cited 2014]. Available from: <http:\/\/www.savic.ac.za\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0120","unstructured":"Government Department of Health, Register of Therapeutic Goods [cited 2014]. Available from: <https:\/\/www.tga.gov.au\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0125","unstructured":"PMDA. Pharmaceuticals and Medical Devices Agency [cited 2014]. Available from: <http:\/\/www.pmda.go.jp\/english\/>."},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4161\/hv.5.3.6986","article-title":"Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control","volume":"5","author":"Kreijtz","year":"2009","journal-title":"Human Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2016.06.059_b0135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4161\/hv.6.2.9899","article-title":"Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses","volume":"6","author":"Pandey","year":"2014","journal-title":"Human Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2016.06.059_b0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/mp060098+","article-title":"Vaccine delivery methods using viral vectors","volume":"4","author":"Br\u00e5ve","year":"2006","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.vaccine.2016.06.059_b0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.biotechadv.2009.02.003","article-title":"Plasmid DNA Vaccine vector design: impact on efficacy, safety and upstream production","volume":"27","author":"Williams","year":"2009","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2016.06.059_b0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fimmu.2014.00005","article-title":"AAV vectors vaccines against infectious diseases","volume":"5","author":"Nieto","year":"2014","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis699","article-title":"Protection against henipavirus infection using recombinant AAV vector vaccines","volume":"207","author":"Ploquin","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0160","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2016.06.059_b0165","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1586\/erv.10.139","article-title":"IMOJEV: a Yellow fever virus-based novel Japanese encephalitis vaccine","volume":"9","author":"Babu Appaiahgari","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2016.06.059_b0170","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1471-4914(01)02048-2","article-title":"Yellow fever vector live-virus vaccines: west Nile virus vaccine development","volume":"7","author":"Arroyo","year":"2001","journal-title":"Trends Mole Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.06.059_b0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7774\/cevr.2013.2.2.97","article-title":"Viral vectors for vaccine applications","volume":"2","author":"Choi","year":"2013","journal-title":"Clin Exp Vaccine Res"},{"issue":"6673","key":"10.1016\/j.vaccine.2016.06.059_b0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.vaccine.2016.06.059_b0185","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mole Therapy: J Am Soc Gene Therapy"},{"issue":"1","key":"10.1016\/j.vaccine.2016.06.059_b0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/fvl.12.122","article-title":"Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses","volume":"8","author":"Mooney","year":"2013","journal-title":"Future Virol"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2016.06.059_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors\u2013friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"issue":"7","key":"10.1016\/j.vaccine.2016.06.059_b0200","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2016.06.059_b0205","doi-asserted-by":"crossref","first-page":"e3548","DOI":"10.1371\/journal.pone.0003548","article-title":"Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice","volume":"3","author":"Croyle","year":"2008","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.vaccine.2016.06.059_b0210","doi-asserted-by":"crossref","first-page":"e73313","DOI":"10.1371\/journal.pone.0073313","article-title":"Low seroprevalent species D adenovirus vectors as influenza vaccines","volume":"8","author":"Weaver","year":"2013","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2016.06.059_b0215","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/CVI.00011-14","article-title":"Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors","volume":"21","author":"Paris","year":"2014","journal-title":"Clin Vaccine Immunol: CVI"},{"issue":"6","key":"10.1016\/j.vaccine.2016.06.059_b0220","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/CVI.00723-13","article-title":"Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors","volume":"21","author":"N\u00e9bi\u00e9","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.06.059_b0225","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nature Commun"},{"issue":"6","key":"10.1016\/j.vaccine.2016.06.059_b0230","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.3390\/v6062392","article-title":"Alphavirus-based vaccines","volume":"6","author":"Lundstrom","year":"2014","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.vaccine.2016.06.059_b0235","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.3390\/v6083055","article-title":"Virus-vectored influenza virus vaccines","volume":"6","author":"Tripp","year":"2014","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.vaccine.2016.06.059_b0240","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0245","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652311795684731","article-title":"MVA and NYVAC as vaccines against emergent infectious diseases and cancer","volume":"11","author":"G\u00f3mez","year":"2011","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2016.06.059_b0250","article-title":"Genetically engineered virus vaccine vectors: environmental risk management challenges","author":"Myhr","year":"2012","journal-title":"Genet Eng \u2013 Basics, New Appl Respons: InTech"},{"issue":"39","key":"10.1016\/j.vaccine.2016.06.059_b0255","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.vaccine.2013.05.092","article-title":"Regulation of poxvirus vectored vaccines","volume":"31","author":"Robertson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.059_b0260","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3389\/fmicb.2014.00439","article-title":"The influence of delivery vectors on HIV vaccine efficacy","volume":"5","author":"Ondondo","year":"2014","journal-title":"Front Microbiol"},{"issue":"16","key":"10.1016\/j.vaccine.2016.06.059_b0265","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2012.02.016","article-title":"Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination","volume":"30","author":"Verheust","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.06.059_b0270","doi-asserted-by":"crossref","first-page":"e16247","DOI":"10.1371\/journal.pone.0016247","article-title":"Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity","volume":"6","author":"Hessel","year":"2011","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2016.06.059_b0275","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.09.4","article-title":"Candidate influenza vaccines based on recombinant modified vaccinia Ankara","volume":"8","author":"Rimmelzwaan","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"39","key":"10.1016\/j.vaccine.2016.06.059_b0280","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","article-title":"Recombinant MVA vaccines: dispelling the myths","volume":"31","author":"Cottingham","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2016.06.059_b0285","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1517\/14712598.2011.571670","article-title":"Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity","volume":"11","author":"Negri","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0290","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.mib.2013.06.002","article-title":"Engineering lactococci and lactobacilli for human health","volume":"16","author":"Berm\u00fadez-Humar\u00e1n","year":"2013","journal-title":"Curr Opin Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0295","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2012.02.008","article-title":"Clinical development of listeria monocytogenes\u2013based immunotherapies","volume":"39","author":"Le","year":"2012","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.vaccine.2016.06.059_b0300","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.3390\/v5092062","article-title":"Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag","volume":"5","author":"Chin\u2019ombe","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.06.059_b0305","unstructured":"IMOJEV Japanese encephalitis vaccine (live, attenuated). Available from: <products.sanofi.com.au\/vaccines\/IMOJEV_AUS_PI.pdf>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0310","unstructured":"WHO. Dengue and severe dengue, Dengvaxia. Sanofi Pasteur; 2015. <http:\/\/www.who.int\/mediacentre\/factsheets\/fs117\/en\/>."},{"key":"10.1016\/j.vaccine.2016.06.059_b0315","unstructured":"BCG live (for intravesical use) TICE BCG. Available from: <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM163039.pdf>."},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.059_b0320","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mole Ther: J Am Soc Gene Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2016.06.059_b0325","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/vaccines3020293","article-title":"Measuring cellular immunity to influenza: methods of detection, applications and challenges","volume":"3","author":"Coughlan","year":"2015","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2016.06.059_b0330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-cell-inducing vaccines \u2013 what\u2019s the future","volume":"135","author":"Gilbert","year":"2012","journal-title":"Immunology"},{"issue":"Pt 11","key":"10.1016\/j.vaccine.2016.06.059_b0335","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1099\/vir.0.024885-0","article-title":"Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A\/H1N1 vaccine in the ferret model","volume":"91","author":"Kreijtz","year":"2010","journal-title":"J Gener Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.06.059_b0340","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1590\/S1517-83822014000400001","article-title":"Live bacterial vaccine vectors: an overview","volume":"45","author":"da Silva","year":"2014","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.vaccine.2016.06.059_b0345","series-title":"The evolution of the Genome","author":"Ryan","year":"2005"},{"issue":"39","key":"10.1016\/j.vaccine.2016.06.059_b0350","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of Modified Vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2016.06.059_b0355","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/mt.2014.109","article-title":"Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations","volume":"22","author":"Kimani","year":"2014","journal-title":"Mole Ther: J Am Soc Gene Ther"},{"key":"10.1016\/j.vaccine.2016.06.059_b0360","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.epidem.2015.02.002","article-title":"Modelling challenges in context: lessons from malaria, HIV, and tuberculosis","volume":"10","author":"Childs","year":"2015","journal-title":"Epidemics"},{"issue":"39","key":"10.1016\/j.vaccine.2016.06.059_b0365","first-page":"413","article-title":"Haemophilus influenzae type b (Hib) vaccination Position Paper","volume":"88","author":"WHO","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"issue":"28\u201329","key":"10.1016\/j.vaccine.2016.06.059_b0370","first-page":"261","article-title":"WHO position paper on hepatitis A vaccines","volume":"87","author":"WHO","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"issue":"47","key":"10.1016\/j.vaccine.2016.06.059_b0375","first-page":"521","article-title":"Meningococcal vaccines; WHO position paper","volume":"86","author":"WHO","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"issue":"43","key":"10.1016\/j.vaccine.2016.06.059_b0380","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper","volume":"89","author":"WHO","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"47","key":"10.1016\/j.vaccine.2016.06.059_b0385","first-page":"461","article-title":"Vaccines against influenza WHO position paper","volume":"87","author":"WHO","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"issue":"40","key":"10.1016\/j.vaccine.2016.06.059_b0390","first-page":"405","article-title":"Hepatitis B vaccines","volume":"84","author":"WHO","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2016.06.059_b0395","unstructured":"FDA news release Flublok [cited 2015]. Available from: <http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm335891.htm>."},{"issue":"4","key":"10.1016\/j.vaccine.2016.06.059_b0400","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/hum.2013.235","article-title":"Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field","volume":"25","author":"Majhen","year":"2014","journal-title":"Hum Gene Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16305102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T05:22:16Z","timestamp":1536297736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16305102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":80,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16305102"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vector-based genetically modified vaccines: Exploiting Jenner\u2019s legacy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}